726697-13-8

Usage

Uses

Used in Medicinal Chemistry:
2,4-DICHLORO-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure allows for exploration in medicinal chemistry for treating various diseases and conditions.
Used in Agrochemical Development:
In the agrochemical industry, 2,4-DICHLORO-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE is utilized as a precursor in the creation of new agrochemicals, potentially enhancing crop protection and yield through targeted pest and disease control.
Used in Organic Chemistry Research:
2,4-DICHLORO-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE serves as a subject of study in organic chemistry, aiding in the understanding of chemical reactivity and the exploration of structure-activity relationships, which is crucial for the advancement of synthetic organic chemistry.

InChI:InChI=1/C7H7Cl2N3/c8-6-4-1-2-10-3-5(4)11-7(9)12-6/h10H,1-3H2

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 

Downstream Products

• 1542708-50-8 N-benzyl-2-(2-methyl-4-(trifluoromethyl)-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1542705-50-9 N-benzyl-2-(4-chloro-2-methyl-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1542705-08-7 N-benzyl-2-(4-fluoro-2-methyl-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1542705-09-8 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carbonitrile 
• 1542708-19-9 N-benzyl-2-(2,4-dimethyl-1H-indol-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1542708-24-6 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-6-carbonitrile 

Relevant academic research and scientific papers

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.